- Conditions
- Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
- Interventions
- BMS-986523, Gemcitabine, Nab-Paclitaxel, Cetuximab, Pembrolizumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • San Antonio, Texas • West Valley City, Utah + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Healthy Adults
- Interventions
- BMS-986089, Placebo matching with BMS-986089
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
- Interventions
- AZD5863
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Jacksonville, Florida • Rochester, Minnesota • New York, New York
- Conditions
- Diabetes Mellitus, Type 2, NIDDM
- Interventions
- PF-04937319, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 4
- States / cities
- Miami, Florida • South Miami, Florida • Cincinnati, Ohio
- Conditions
- Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3
- Interventions
- HMB-002 (Part A), HMB-002 (Part B), HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US)
- Drug
- Lead sponsor
- Hemab ApS
- Industry
- Eligibility
- 16 Years to 69 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
- Conditions
- Pain, Acute
- Interventions
- TRV130 1.5 mg, TRV130 3 mg, TRV130 4.5 mg, Morphine 10 mg, Placebo
- Drug
- Lead sponsor
- Trevena Inc.
- Industry
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Pelizaeus-Merzbacher Disease
- Interventions
- ION356
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years to 17 Years · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Philadelphia, Pennsylvania • Salt Lake City, Utah
- Conditions
- Advanced Cancer, Metastatic Cancer, Neoplasms, Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes
- Interventions
- MRX-2843
- Drug
- Lead sponsor
- Meryx, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Chapel Hill, North Carolina
- Conditions
- Cutaneous Lupus Erythematosus
- Interventions
- CC-11050, Placebo
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 19
- States / cities
- Rogers, Arkansas • Los Angeles, California • San Diego, California + 15 more
- Conditions
- Pulmonary Hypertension
- Interventions
- Dexmedetomidine
- Drug
- Lead sponsor
- Aruna Nathan
- Other
- Eligibility
- 8 Years to 21 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Dendritic Cell -Mediated Rheumatic Diseases
- Interventions
- VIB1116, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 8
- States / cities
- Anniston, Alabama • Clearwater, Florida • Jacksonville, Florida + 5 more
- Conditions
- Healthy Adult Subjects, Healthy Elderly Subjects
- Interventions
- BIIB118, Melatonin
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- South Miami, Florida
- Conditions
- Solid Tumors, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
- Interventions
- PLX51107
- Drug
- Lead sponsor
- Plexxikon
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 5
- States / cities
- New York, New York • Columbus, Ohio • Philadelphia, Pennsylvania + 2 more
- Conditions
- Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Interventions
- Povetacicept
- Drug
- Lead sponsor
- Alpine Immune Sciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Valencia, California + 14 more
- Conditions
- Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IIIA Non-small Cell Lung Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx
- Interventions
- erlotinib hydrochloride, pharmacological study, pharmacogenomic studies, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Adult Growth Hormone Deficiency
- Interventions
- ALTU-238
- Drug
- Lead sponsor
- Altus Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 3
- States / cities
- Louisville, Kentucky • Galveston, Texas • San Antonio, Texas
- Conditions
- Prevention
- Interventions
- Tenofovir 1% vaginal gel
- Drug
- Lead sponsor
- CONRAD
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 194 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 4
- States / cities
- Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania • Houston, Texas + 1 more
- Conditions
- Parkinson's Disease
- Interventions
- CD-LD IR, IPX203 180 mg, IPX203 270 mg, Rytary 195 mg, Rytary 145 mg
- Drug
- Lead sponsor
- Impax Laboratories, LLC
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 8 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- GK1-399 (formerly TTP399), Placebo
- Drug
- Lead sponsor
- vTv Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 11
- States / cities
- Little Rock, Arkansas • Chula Vista, California • DeLand, Florida + 8 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- ATI-450, Placebo oral tablet
- Drug
- Lead sponsor
- Aclaris Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Fort Smith, Arkansas • Encino, California + 17 more
- Conditions
- Castration-resistant Prostate Cancer, CRPC
- Interventions
- VT-464: given orally once daily in 28 day cycles
- Drug
- Lead sponsor
- Innocrin Pharmaceutical
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 5
- States / cities
- Tampa, Florida • Omaha, Nebraska • Durham, North Carolina + 2 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- GSK2330672, Placebo, Sitagliptin, Metformin
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 30 Years to 64 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 4
- States / cities
- Chula Vista, California • Miami, Florida • Baltimore, Maryland + 1 more
- Conditions
- Healthy
- Interventions
- PF-04965842, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Solid Tumor
- Interventions
- ASN004
- Drug
- Lead sponsor
- Kirilys Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Austin, Texas • San Antonio, Texas + 1 more